Remarkably, approximately 94% (15 out of 16) transformed components evolved into neuroendocrine-high subtypes (SCLC-A and SCLC-N), accompanied by a statistically significant decrease in EGFR expression (p < 0.001) at both transcriptomic and protein levels. The gene discussed is EGFR; the disease is small cell lung carcinoma.